What is Eiger BioPharmaceuticals 6-1 Month Momentum %?
6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-01), Eiger BioPharmaceuticals's 6-1 Month Momentum % is -36.08%.
The industry rank for Eiger BioPharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:
EIGRQ's 6-1 Month Momentum % is ranked worse than 82.41% of 1518
companies
in the Biotechnology industry
Industry Median: 4.14
vs EIGRQ: -36.08
Competitive Comparison of Eiger BioPharmaceuticals's 6-1 Month Momentum %
For the Biotechnology subindustry, Eiger BioPharmaceuticals's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eiger BioPharmaceuticals's 6-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Eiger BioPharmaceuticals's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Eiger BioPharmaceuticals's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Eiger BioPharmaceuticals 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Eiger BioPharmaceuticals's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Eiger BioPharmaceuticals (Eiger BioPharmaceuticals) Business Description
Eiger BioPharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
EIGRQ has been successfully added to your